Project Grant HT94252510101
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$2.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
The University of Massachusetts Medical School was awarded a $836,992 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, will fund research to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The research aims to transform healthcare for military service members, veterans, and the broader...
The University of Massachusetts Medical School was awarded a $1,005,000 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to develop pad inhibitors for the treatment of amyotrophic lateral sclerosis (ALS). The award, which commenced on September 30, 2024, will support research activities through September 29, 2026. The Medical School's Grants and Contracts Administration division, doing business as UMms, will lead the project...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $680,757 project grant to New York University School of Medicine to conduct research titled "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation." The grant, effective July 1, 2025 through June 30, 2028, will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $798,272 project grant to The Johns Hopkins University on March 15, 2025. The grant will fund a 2-year research project titled "Testing the Use of WNT Inhibitors as a Therapeutic to Reverse TDP-43 Dysfunction in ALS." The research aims to develop novel therapeutic approaches for amyotrophic lateral sclerosis (ALS) by investigating the use of WNT inhibitors to address TDP-43 protein...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,078,882 to the Sanford Burnham Prebys Medical Discovery Institute to conduct advanced chemical engineering research on amyotrophic lateral sclerosis (ALS). The research aims to take a more sophisticated, multimodal approach to understanding the therapeutic actions of donor and host neural stem cells in ALS. The award includes a sub-grant to the J. David...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
The federal Project Grant award, valued at $2,490,000.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is for the "Development of a VAV2 Antisense Oligonucleotide Therapeutic for ALS" at the University of Southern California (USC). This award, effective March 1, 2025 through February 28, 2027, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
The Department of Defense's Defense Health Agency has awarded a $789,903 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Universita' Degli Studi DI Pavia in Italy. The grant, effective from September 1, 2024 through August 31, 2026, will fund research to enhance the GAS6/AXL signaling pathway as a potential neuroprotective and immunomodulatory strategy for tackling amyotrophic lateral sclerosis (ALS). As the prime awardee, Universita' Degli Studi DI...